Cancer is a complex and heterogeneous disease, where even patients with the same cancer type may respond differently to treatment regimens. Predicting the therapeutic effects of drugs on cancer based on cancer characteristics is a critical aspect of precision oncology. Currently, most anticancer drug response(CDR) prediction methods rely on extracting features from the cell line-drug bipartite composition. However, these methods often fail to adequately capture the features of both drugs and cell lines, ignoring the homogeneous features of cell lines and drugs and their correlation with deep heterogeneous features. To address these challenges, we propose a novel prediction framework that leverages a heterogeneous and homogeneous hybrid graph neural network named H$^{3}$CDR. H$^{3}$CDR learns the similarity features of cancer cell lines and drugs by fusing their multi-omics data. Additionally, a multi-branch network is employed to extract features from both cell lines and drugs, enabling the identification of potential features. Extensive experiments on the GDSC and CCLE databases demonstrate the superiority of our model. Evaluated by five-fold cross-validation, H$^{3}$CDR achieves an area under the ROC curve (AUC) of 0.8772 and an area under the precision-recall curve (AUPRC) of 0.8819 on the GDSC dataset.

Drug repositioning (DR) presents a cost-effective strategy for drug development by identifying novel therapeutic applications for existing drugs. Current computational approaches remain constrained by their inability to synergize localized substructure patterns with global network semantics, leading to overreliance on data augmentation to mitigate latent drug-disease association (DDA) information gaps. To address these limitations, we present multi-view stacked graph convolutional network (MVSGDR), a novel DR framework featuring three technical innovations: (i) multi-view stacked module that enables depth-wise feature enhancement through hierarchical aggregation of multi-hop neighborhood interactions across distinct graph convolutional layers; (ii) bi-level subgraph transformer module that decomposes DDAs into METIS (a graph partitioning tool) informative subgraphs for breadth-wise analysis of external and internal subgraph drug-disease relationships; and (iii) negative sampling balancing strategy that mitigates sample imbalance through negative sample synthesis. Extensive 10-fold cross-validation experiments across four benchmark datasets confirm MVSGDR's superior performance, demonstrating its statistically significant improvements over existing methods. Moreover, case studies further validate MVSGDR's potential utility through identification of previously unreported DDAs with supporting literature evidence.

The ingestible capsule robot has shown significant promise for non-invasive diagnosis and drug delivery within the gastrointestinal tract. Locomotion control of the capsule robot requires real-time, accurate localization and angle estimation from ultrasound images. This paper introduces a novel CNN model with spatially adaptive Gaussian distribution, which can simultaneously finish the localization and angle estimation of capsule robots in US images. Specifically, we propose a robot-adaptive label assignment strategy using an elliptical Gaussian to better suit the shape and orientation of the capsule robot. Additionally, we employ a novel bounding box representation for capsule robot localization to encode predictions from the CNN model. Experimental results demonstrate that our method finishes real-time localization and angle estimation of capsule robots at approximately 48 frames per second. Moreover, our approach achieves a small localization error of 0.16 mm and a high angle estimation accuracy of 99.85%. The method developed, utilizing spatially adaptive Gaussian distribution, holds practical significance in achieving accurate and real-time position and angle feedback for the locomotion control of capsule robots.

Dynamic contrast-enhanced ultrasound (CEUS) imaging can reflect the microvascular distribution and blood flow perfusion, thereby holding clinical significance in distinguishing between malignant and benign thyroid nodules. Notably, CEUS offers a meticulous visualization of the microvascular distribution surrounding the nodule, leading to an apparent increase in tumor size compared to gray-scale ultrasound (US). In the dual-image obtained, the lesion size enlarged from gray-scale US to CEUS, as the microvascular appeared to be continuously infiltrating the surrounding tissue. Although the infiltrative dilatation of microvasculature remains ambiguous, sonographers believe it may promote the diagnosis of thyroid nodules. We propose a deep learning model designed to emulate the diagnostic reasoning process employed by sonographers. This model integrates the observation of microvascular infiltration on dynamic CEUS, leveraging the additional insights provided by gray-scale US for enhanced diagnostic support. Specifically, temporal projection attention is implemented on time dimension of dynamic CEUS to represent the microvascular perfusion. Additionally, we employ a group of confidence maps with flexible Sigmoid Alpha Functions to aware and describe the infiltrative dilatation process. Moreover, a self-adaptive integration mechanism is introduced to dynamically integrate the assisted gray-scale US and the confidence maps of CEUS for individual patients, ensuring a trustworthy diagnosis of thyroid nodules. In this retrospective study, we collected a thyroid nodule dataset of 282 CEUS videos. The method achieves a superior diagnostic accuracy and sensitivity of 89.52% and 94.75%, respectively. These results suggest that imitating the diagnostic thinking of sonographers, encompassing dynamic microvascular perfusion and infiltrative expansion, proves beneficial for CEUS-based thyroid nodule diagnosis.